Thursday, May 17, 2007 5:11:01 PM
But to be used clinically, each individual would have to be screened genetically to determine if they had specific genetic sequences (cheaply, by haplotypes, if correlation is high) or by direct sequencing.
If the susceptibility/responder issue in question can be causally associated with a known genetic variance there is no need for any other screening method. Simply screen for the variance and get on with it.
The 'value' of bio-geographical association is when the causal variance is unknown. By extracting the bio-geographical trends from a population of responders, it is sometimes possible to determine a general locus for the unknown variance. Essentially the location where the variance first entered the gene pool. Once established it is then possible to narrow the pool of 'responders' via a scan for that specific bio-geographical ancestry.
It is only a tool to help with such a discovery process, it can never be used clinically due to the obvious lack of specificity that it provides.
regards,
frog
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM